In this article, we will discuss Trametinib and Venous Thromboembolism. So, let’s get started.
Trametinib and Venous Thromboembolism
In the COMBI-d study, deep venous thrombosis (DVT) and pulmonary embolism (PE) occurred in 2.8% of patients receiving trametinib and dabrafenib. In the COMBI-AD study, DVT and PE occurred in 2% of patients receiving trametinib and dabrafenib. In Study BRF113928, DVT and PE occurred in 4.3% of patients receiving trametinib and dabrafenib.
Advise patients to immediately seek medical care if they develop symptoms of DVT or PE, such as shortness of breath, chest pain, or arm or leg swelling. Permanently discontinue trametinib for life threatening PE.
Withhold trametinib for uncomplicated DVT and PE for up to 3 weeks; if improved, trametinib may be resumed at a lower dose level.